JP2014530253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530253A5 JP2014530253A5 JP2014537186A JP2014537186A JP2014530253A5 JP 2014530253 A5 JP2014530253 A5 JP 2014530253A5 JP 2014537186 A JP2014537186 A JP 2014537186A JP 2014537186 A JP2014537186 A JP 2014537186A JP 2014530253 A5 JP2014530253 A5 JP 2014530253A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 10
- 230000002378 acidificating effect Effects 0.000 claims 5
- 206010065973 Iron Overload Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547932P | 2011-10-17 | 2011-10-17 | |
| US61/547,932 | 2011-10-17 | ||
| PCT/US2012/060650 WO2013059347A1 (en) | 2011-10-17 | 2012-10-17 | Methods and compositions for treating ineffective erythropoiesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017022176A Division JP6383821B2 (ja) | 2011-10-17 | 2017-02-09 | 無効赤血球生成を処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530253A JP2014530253A (ja) | 2014-11-17 |
| JP2014530253A5 true JP2014530253A5 (enExample) | 2015-12-10 |
| JP6092883B2 JP6092883B2 (ja) | 2017-03-08 |
Family
ID=48141315
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537186A Active JP6092883B2 (ja) | 2011-10-17 | 2012-10-17 | 無効赤血球生成を処置するための方法および組成物 |
| JP2017022176A Active JP6383821B2 (ja) | 2011-10-17 | 2017-02-09 | 無効赤血球生成を処置するための方法および組成物 |
| JP2018147507A Active JP6796626B2 (ja) | 2011-10-17 | 2018-08-06 | 無効赤血球生成を処置するための方法および組成物 |
| JP2020140889A Pending JP2020186277A (ja) | 2011-10-17 | 2020-08-24 | 無効赤血球生成を処置するための方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017022176A Active JP6383821B2 (ja) | 2011-10-17 | 2017-02-09 | 無効赤血球生成を処置するための方法および組成物 |
| JP2018147507A Active JP6796626B2 (ja) | 2011-10-17 | 2018-08-06 | 無効赤血球生成を処置するための方法および組成物 |
| JP2020140889A Pending JP2020186277A (ja) | 2011-10-17 | 2020-08-24 | 無効赤血球生成を処置するための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20130243743A1 (enExample) |
| EP (3) | EP3520805B1 (enExample) |
| JP (4) | JP6092883B2 (enExample) |
| KR (4) | KR20220075438A (enExample) |
| CN (3) | CN107693776A (enExample) |
| AU (4) | AU2012326207B2 (enExample) |
| BR (3) | BR122019023174B1 (enExample) |
| CA (1) | CA2852683A1 (enExample) |
| DK (2) | DK3875104T3 (enExample) |
| EA (2) | EA202090053A3 (enExample) |
| ES (3) | ES2869168T3 (enExample) |
| HK (2) | HK1250341A1 (enExample) |
| WO (1) | WO2013059347A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2332977T3 (en) | 2004-07-23 | 2016-02-29 | Acceleron Pharma Inc | ActRII receptor polypeptides |
| CA3045808C (en) | 2005-11-23 | 2022-08-16 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for promoting bone growth |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
| TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| WO2008100384A2 (en) | 2007-02-09 | 2008-08-21 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| TW201919685A (zh) | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CA2764890A1 (en) | 2009-06-08 | 2010-12-16 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| CN104805105A (zh) | 2009-06-12 | 2015-07-29 | 阿塞勒隆制药公司 | 截短的actriib-fc融合蛋白 |
| CA2773494A1 (en) * | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| CA2890217C (en) | 2012-11-02 | 2021-07-20 | Yifu FANG | Activin-actrii antagonists and uses for treating bone and other disorders |
| WO2015143403A1 (en) * | 2014-03-21 | 2015-09-24 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11 |
| AP2016009549A0 (en) * | 2014-04-18 | 2016-11-30 | Acceleron Pharma Inc | Methods for increasing red blood cell levels and treating sickle-cell disease |
| AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| LT3227675T (lt) | 2014-12-03 | 2023-06-12 | Celgene Corporation | Aktivino actrii antagonistai ir naudojimas mielodisplastiniam sindromui gydyti |
| RU2733492C2 (ru) | 2015-04-22 | 2020-10-02 | Байоджен Ма Инк. | Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией |
| JP6976859B2 (ja) * | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) * | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| CA3031909A1 (en) | 2016-07-27 | 2018-02-01 | Acceleron Pharma Inc. | Methods and compositions for treating myelofibrosis |
| KR102595559B1 (ko) | 2016-10-05 | 2023-10-30 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN110461349B (zh) | 2016-11-10 | 2024-08-13 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| US20200101134A1 (en) * | 2017-06-14 | 2020-04-02 | Celgene Corporation | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CA3087008A1 (en) | 2018-01-12 | 2019-07-18 | Keros Therapeutics, Inc. | Activin receptor type iib variants and methods of use thereof |
| JP7405772B2 (ja) | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| AU2021270458A1 (en) | 2020-05-13 | 2022-11-10 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| DE69636866D1 (en) | 1995-04-11 | 2007-03-15 | Gen Hospital Corp | Reverse "two-hybrid"-systeme |
| US5807839A (en) * | 1997-04-15 | 1998-09-15 | Advanced Viral Research Corp. | Method for stimulating red blood cell production |
| ATE322681T1 (de) | 1999-01-21 | 2006-04-15 | Metamorphix Inc | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| WO2004034962A2 (en) * | 2002-10-15 | 2004-04-29 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
| DK2332977T3 (en) | 2004-07-23 | 2016-02-29 | Acceleron Pharma Inc | ActRII receptor polypeptides |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TW201919685A (zh) * | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| RU2642302C1 (ru) * | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
-
2012
- 2012-10-17 EA EA202090053A patent/EA202090053A3/ru unknown
- 2012-10-17 KR KR1020227017193A patent/KR20220075438A/ko not_active Ceased
- 2012-10-17 ES ES19161424T patent/ES2869168T3/es active Active
- 2012-10-17 JP JP2014537186A patent/JP6092883B2/ja active Active
- 2012-10-17 BR BR122019023174-5A patent/BR122019023174B1/pt active IP Right Grant
- 2012-10-17 KR KR1020197025484A patent/KR102079482B1/ko active Active
- 2012-10-17 EP EP19161424.7A patent/EP3520805B1/en active Active
- 2012-10-17 EP EP12842601.2A patent/EP2797620B1/en active Active
- 2012-10-17 BR BR122019023166-4A patent/BR122019023166B1/pt active IP Right Grant
- 2012-10-17 BR BR112014009528-0A patent/BR112014009528B1/pt active IP Right Grant
- 2012-10-17 KR KR1020147013325A patent/KR20140084211A/ko not_active Ceased
- 2012-10-17 EA EA201490809A patent/EA034563B1/ru not_active IP Right Cessation
- 2012-10-17 ES ES12842601T patent/ES2741477T3/es active Active
- 2012-10-17 DK DK21153891.3T patent/DK3875104T3/da active
- 2012-10-17 CN CN201711069457.8A patent/CN107693776A/zh active Pending
- 2012-10-17 AU AU2012326207A patent/AU2012326207B2/en active Active
- 2012-10-17 WO PCT/US2012/060650 patent/WO2013059347A1/en not_active Ceased
- 2012-10-17 DK DK19161424.7T patent/DK3520805T3/da active
- 2012-10-17 EP EP21153891.3A patent/EP3875104B1/en active Active
- 2012-10-17 CN CN201711069431.3A patent/CN107837390A/zh active Pending
- 2012-10-17 ES ES21153891T patent/ES3010483T3/es active Active
- 2012-10-17 KR KR1020207004201A patent/KR20200019261A/ko not_active Ceased
- 2012-10-17 US US13/654,191 patent/US20130243743A1/en not_active Abandoned
- 2012-10-17 CN CN201280061672.2A patent/CN103987403B/zh active Active
- 2012-10-17 CA CA2852683A patent/CA2852683A1/en active Pending
-
2017
- 2017-01-23 US US15/413,184 patent/US20170137791A1/en not_active Abandoned
- 2017-02-09 JP JP2017022176A patent/JP6383821B2/ja active Active
- 2017-03-08 AU AU2017201580A patent/AU2017201580B2/en active Active
- 2017-07-28 US US15/663,361 patent/US20170327800A1/en not_active Abandoned
-
2018
- 2018-07-30 HK HK18109792.1A patent/HK1250341A1/zh unknown
- 2018-08-06 JP JP2018147507A patent/JP6796626B2/ja active Active
- 2018-09-26 HK HK18112295.7A patent/HK1252940A1/zh unknown
- 2018-10-11 AU AU2018247262A patent/AU2018247262B2/en active Active
-
2020
- 2020-08-07 US US16/987,756 patent/US20210207107A1/en active Pending
- 2020-08-24 JP JP2020140889A patent/JP2020186277A/ja active Pending
- 2020-12-09 AU AU2020286229A patent/AU2020286229A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530253A5 (enExample) | ||
| WO2013080147A3 (en) | Anticancer fusion protein | |
| JP2016509011A5 (enExample) | ||
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| EP3363458A3 (en) | A peptide | |
| JP2012082206A5 (enExample) | ||
| MX2016016063A (es) | Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas. | |
| JP2014513952A5 (enExample) | ||
| WO2010010551A3 (en) | Angiopoietin derived peptides | |
| WO2014159822A3 (en) | Human antibodies to respiratory syncytial virus f protein and methods of use thereof | |
| WO2013098755A3 (en) | Anticancer fusion protein | |
| JP2011024595A5 (enExample) | ||
| BR112014029966A2 (pt) | proteínas de fator de crescimento de fibroblasto 21 | |
| HK1200842A1 (en) | Proteins with improved half-life and other properties | |
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| EA202090053A2 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| JP2012115277A5 (enExample) | ||
| WO2012007839A3 (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| WO2017041001A3 (en) | Insulin immunoglobulin fusion proteins | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| RU2017114673A (ru) | Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение | |
| JP2016536357A5 (enExample) | ||
| WO2012143477A3 (en) | Anticancer fusion protein |